Dr Cliff Elcombe Biomedical Research Centre Ninewells Hospital

1
Dr Cliff ElcombeBiomedical Research
CentreNinewells Hospital Medical
SchoolUniversity of Dundee

• Risk Perception, Risk Assessment and Mechanisms
  of Toxicity

2
(No Transcript)
3
(No Transcript)
4
(No Transcript)
5
(No Transcript)
6
Hazard and Risk

• Hazard
• Intrinsic property of the chemical
• The potential for harm
• Risk
• Hazard x exposure (dose and time)
• The chance (probability) that harm will actually
  occur

7
The Average Americans Chances of Dying this Year
of
Heart disease
1 in 300
Cancer
1 in 700
Motor vehicle accident
1 in 4,200
Suicide
1 in 9,300
Homocide
1 in 12,000
Fire
1 in 31,000
Electrocution
1 in 230,000
Tornado
1 in 3.3 million
Living near nuclear plant
1 in 5 million
2 quarts of "TCE water" (5 ppb)
1 in 70 million
8
Concentration Analogies
One Part Per Million is

• one automobile in bumper-to-bumper traffic from
  Cleveland to San Francisco
• one pancake in a stack four miles high
• 1 inch in 16 miles
• one minute in two years
• one cent in 10,000

9
Concentration Analogies
One Part Per Billion is

• one 4-inch hamburger in a chain of hamburgers
  circling the earth at the equator two-and-a-half
  times
• one sheet in a roll of toilet paper stretching
  from New York to London
• one second of time in 32 years

10
Perceived Risk Ratings
11
A Selection of Natural Carcinogens

• anise
• apples
• bananas
• basil
• brocolli
• brussel sprouts
• cabbage
• carrots
• cauliflower
• celery
• cinnamon
• cloves
• cocoa
• comfrey tea
• fennel
• grapefruit juice

• honey dew melon
• horseradish
• kale
• mushrooms
• mustard
• nutmeg
• orange juice
• parsely
• parsnips
• peaches
• black pepper
• pineapples
• radishes
• raspberries
• tarragon
• turnips

12
Carcinogenic Risk of "Alar- Contaminated" Apple
Juice

• 15 pints (9.6 L) of apple juice per day has a
  carcinogenic
• risk equivalent to
• 1 mushroom (15g) per day
• 1/3 of a peanut butter sandwich
• 100g celery
• 100g cabbage
• 1/100 pint (6.5ml) of beer
• 1/2 teaspoon (2.5ml) of wine
• 15 minutes in a swimming pool

13
The Stages of Risk Assessment
Hazard Identification
Risk Estimation
Risk Evaluation
Risk Management
14
Hazard Identification

• Human Studies
• Short Term Tests and Structure Activity
• Animal Studies

15
Hazard Identification

• Human Studies
• epidemiology
• retrospective
• low statistical power
• uncertain exposure estimates
• volunteer studies
• prospective
• usually not ethical

16
Hazard Identification
Short Term Tests and Theoretical
Approaches
surrogate measurements
qualitative
17
Hazard Identification
Animal Studies
high to low dose extrapolation
route of exposure
18
Animal Studies in Toxicological Evaluation

• Acute Toxicity ("LD50")
• rats/mice
• Irritancy/corrosivity/sensitization
• guinea pigs/rabbits
• Mutagenicity, clastogenicity
• in vivo and in vitro
• Subacute/subchronic toxicity
• rats/mice/dogs

• Carcinogenicity
• rats and mice
• Reproductive toxicology
• rats/mice/rabbits
• teratology
• foetal toxicity
• multigeneration

19
Risk Estimation
Safety Factor Approach
Mathematical Models
20
Risk Estimation - Safety Factor Approach

• ADI NOEL / SF
• ADI acceptable (allowable) daily intake
• NOEL no observable effect level
• SF safety factor

21
Hypothetical Dose-response
35
30
25
20
Tumour Incidence ()
15
10
5
0
0
200
400
600
800
1,000
1,200
Dose (mg/kg)
22
Application of a 100-fold safety factor to
convert a NOAEL in animals into an ADI for humans
10 fold
10 fold
Human variability
Species differences
23
Risk Estimation- Mathematical Models

• Virtually Safe Dose
• Linear Extrapolation
• One-hit Models
• Multi-hit Models
• Multistage Models
• Weibull Model
• Physiologically-based Pharmacokinetic Models

24
Linearised Model
1,000,000
100,000
10,000
1,000
Risk per 1,000,000
100
10
1
1
100
1,000
10,000
100,000
10
Dose (ppm in diet)
VSD ("virtually safe dose")
25
Metabolic Saturation!
26
Interspecies Comparisons

• Absorbtion, distribution, metabolism and
  excretion
• Mechanisms

27
The Exposure-Dose-Response Paradigm for
Carcinogens and Toxicants
oral inhalation dermal
Exposure
Blood concentration
Tissue dose of toxic moiety
metabolic activation/deactivation accumulation/exc
retion
Toxic moiety-target interaction
eg. transcriptional activation, cofactor
depletion, mutation, enzyme inhibition, etc.
acute, eg. cell death subacute, eg. organ
growth chronic, eg. cancer
Toxic response
28
Physiologically-based Pharmacokinetic Model for
Volatile Organic Chemicals
29
Risk Evaluation and Management

• What level of risk is acceptable?
• how safe is safe enough?
• risk-benefit analysis
• perception of relative risk
• technical considerations
• socioeconomics
• politics

30
Mechanisms in Hazard and Risk Assessment
31
Classification of Carcinogens

• Genotoxic
• Nongenotoxic
• cytotoxic
• mitogenic

32
Liver Growth Carcinogens

• Hyperplasia
• Stimulate cell proliferation (acute and/or
  chronic)
• Inhibit apoptosis
• Hypertrophy
• Organelle proliferation
• SER
• Peroxiosmes

33
Characteristics of the Peroxisome Proliferation
Phenomenon in Rats

• Hepatomegaly
• Proliferation of peroxisomes and smooth
  endoplasmic reticulum
• Induction of peroxisomal fatty acid oxidising
  enzymes
• Induction of CYP 4A1
• Stimulation of replicative DNA synthesis
• Inhibition of apoptosis
• Hepatocellular tumours in long term studies

34
What is the Mechanism of Hepatocarcinogenesis?

• Receptor-mediated
• Reactive oxygen/oxidative stress
• Stimulation of S-phase
• Inhibition of apoptosis
• ??????????
• Biological plausibility?

35
Chemicals Eliciting Peroxisome Proliferation in
Rats and/or Mice
36
Model of Peroxisome Proliferator Action
Peroxisome Proliferation, Growth Regulation and
Hepatocarcinogenesis
37
PPARa Knockout Mouse

• No hypolipidaemia
• No hepatomegaly
• No peroxisome proliferation
• No peroxiosomal enzyme induction
• No CYP4A induction
• No stimulation of DNA synthesis
• No inhibition of apoptosis
• No hepatocellular tumours

38
(No Transcript)
39
Diethylhexyladipate Toxicology

• Very low acute toxicity
• Not irritant/corrosive/sensitizer
• Non-mutagenic
• No reproductive effects
• Hepatocarcinogen in mice not rats
• Potential Human Carcinogen?

40
In Vivo/In Vitro Extrapolation
Animal in vitro
Human in vitro
Animal in vivo
Human in vivo
?
41
Metabolism of Diethylhexyladipate (DEHA)
HOOC(CH2)4COOH

HOOCCHCH2CH2CHCH3
HOOCCHCH2CH2CH2CH3
CH2CH3
CH2CH3
OH
HO0CCHCH2CH2CCH3
O
CH2CH3
42
Peroxisome Proliferation in Mouse Hepatocyte
Cultures - DEHA and Metabolites
3,000
EHA
2,500
2,000
EH
MEHA
1,500
Peroxisome Proliferation ( control)
1,000
OH-EHA
Keto-EHA
500
EHdiA
AA
0
0
1,200
200
400
600
800
1,000
Concentration (microMolar)
43
Species Differences in Response - EHA
3,000
Mouse
2,500
2,000
1,500
Peroxisome Proliferation ( control)
1,000
Rat
Human
500
Guinea pig
Marmoset
0
0
200
400
600
800
1,000
1,200
Concentration (microMolar)
44
Dose-response to Peroxisome Proliferators
Liver growth
Tumours
Response
1
3
2
Dose
Threshold for early events
Tumour threshold
45
Summary

• Hazard and risk are not the same
• Perception of risk does not necessarily relate to
  actual risk
• Risk assessment should not be a purely
  mathematical exercise
• Mechanisms of toxicity should play a major role
  in risk assessment

46
Good Web Sites for Risk Assessment
A Journalist's Handbook on Environmental Risk
Assessment
http//ruby.fgcu.edu/Courses/Twimberley/IDS3920/ma
in.html
Epidemiology for Journalists
http//www.facsnet.org/tools/ref_tutor/epidem/inde
x.php3 http//www.facsnet.org/tools/ref_tutor/risk
/index.php3
General Site for Risk Assessment Information
http//riskcenter.doe.gov/whatisrisk/riskassessmen
t.cfm